Techh.info/techtechnology hourly

Immunotherapy

headlines texts
21.08.2019
11:02 News-Medical.NetFDA clears its IND for new immunotherapeutic for treating prostate cancer

Calibr, the drug development division of Scripps Research, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer.

Скрыть анонс
20.08.2019
08:50 News-Medical.NetResearchers develop new gene editing system that could be used for anticancer immunotherapy

Dr. Mihue Jang and her group at the Center for Theragnosis of the Korea Institute of Science and Technology announced that they have developed a new gene-editing system that could be used for anticancer immunotherapy through the simultaneous suppression of proteins that interfere with the immune system expressed on the surface of lymphoma cells and activation of cytotoxic T lymphocyte, based on the results of joint research conducted with Prof. Seokmann Hong and his group at Sejong University.

Скрыть анонс
06:13 News-Medical.NetLipid signaling pathway may enhance T cell-mediated immunotherapy

The immune system surveils our body looking for things that don't belong, often bacteria and viruses. While cancer cells are abnormal cells that undergo unregulated cell growth, they are good at evading detection by the immune system.

Скрыть анонс
19.08.2019
19:16 ScienceDaily.comNew lipid signaling target may improve T cell immunotherapy

T cell immunotherapy uses the immune system to kill cancer cells. To increase the efficacy of this new treatment, researchers aimed to discover a master regulator of T cell fate. The signaling lipid sphingosine 1-phosphate (S1P) influences the T cell lineage: high levels of S1P lead to an inhibitory regulatory T cell phenotype, while low levels of S1P lead to a central memory-like phenotype, which exhibit increased anti-cancer functions.

Скрыть анонс
16.08.2019
10:53 Technology.orgBalance of “Stop” and “Go” Signaling Could Be Key to Cancer Immunotherapy Response

A crucial signaling pathway that can tell the immune system to fight off cancer can also be co-opted

Скрыть анонс
14.08.2019
18:59 CancerNetwork.comCan Immunotherapy Improve Survival in NSCLC?

A new meta-analysis compared survival in patients with advanced non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.

Скрыть анонс
13.08.2019
23:50 CancerNetwork.comCan Immunotherapy Play a Role in Pancreatic Ductal Adenocarcinoma?

A combination of durvalumab and tremelimumab was tested on patients with metastatic pancreatic ductal adenocarcinoma.

Скрыть анонс
12.08.2019
16:42 News-Medical.NetNew T cell detection method promises personalized immunotherapy for melanomas

An important new study shows that better T cell detection is now possible using revolutionary technology. T cells are a type of lymphocyte, which in turn belongs to the diverse family of immune cells. They take part in cancer fighting as well as in most other immune responses.

Скрыть анонс
14:49 ClinicalOncology.comThe Debate Over When to Stop Immunotherapy

Fort Worth, Texas—Although immunotherapy delivers durable responses and survival benefits in patients with previously untreatable tumors, concerns about frequent and often severe immune-related adverse effects (AEs) persist.

Скрыть анонс
11.08.2019
06:43 News-Medical.NetAdvanced tools could lead to better cancer immunotherapy

In the journal Science Immunology, researchers from DTU Health Technology and Jacobs University in Bremen have just published their cutting-edge research demonstrating advancement in detection of a certain type of immune cells, called T cells.

Скрыть анонс
10.08.2019
00:23 ScienceDaily.comBetter tools, better cancer immunotherapy

Researchers have developed an important new tool towards producing therapies for cancer patients using the patient's own cells

Скрыть анонс
07.08.2019
12:44 Technology.orgNovel Immunotherapy May Prevent Brain Metastases

Brain metastases are the final, lethal consequence of many aggressive cancers, and researchers are racing to discover ways

Скрыть анонс
06.08.2019
23:46 CancerNetwork.comImmunotherapy Failure in Pancreatic Cancer Reveals Potential Path Forward

Negative trial findings suggest immune checkpoint inhibitors may not be the best type of immunotherapy to treat pancreatic cancer.

Скрыть анонс
09:38 News-Medical.NetNew research explains why some cancers don't respond to immunotherapy

New research has uncovered a mechanism thought to explain why some cancers don't respond to a widely used form of immunotherapy called "checkpoint inhibitors" or anti-PD-1.

Скрыть анонс
05.08.2019
18:02 ScienceDaily.comResearchers make immunotherapy work for treatment-resistant lymphoma

Researchers have developed a way to use immunotherapy drugs against treatment-resistant non-Hodgkin's lymphomas for the first time by combining them with stem cell transplantation, an approach that also dramatically increased the success of the drugs in melanoma and lung cancer.

Скрыть анонс
09:49 Technology.orgLiver Damage More Commonly Due to Malignant Tumors than Cancer Immunotherapy Drug

Immunotherapy as a treatment for advanced solid organ tumors has rapidly evolved over the past decade, often yielding

Скрыть анонс
31.07.2019
20:21 Nature.ComCD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

Скрыть анонс
19:48 Medscape.ComFirst Approval for Immunotherapy for Esophageal Cancer

Esophageal cancer has now joined the list of tumor types that can be treated with a checkpoint inhibitor — in this case, with pembrolizumab (Keytruda).

Скрыть анонс
26.07.2019
13:10 Technology.orgEncephalitis identified as rare toxicity of immunotherapy treatment

After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram

Скрыть анонс
23.07.2019
19:51 Medscape.ComCould TNF Blocker Cure Immunotherapy-Induced Diabetes?

Case report points to possible novel therapeutic approach to an increasingly common side effect of successful cancer therapy with immune checkpoint inhibitors.

Скрыть анонс
22.07.2019
21:53 ScienceDaily.comEncephalitis identified as rare toxicity of immunotherapy treatment

Researchers chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Скрыть анонс
20:35 News-Medical.NetResearchers identify encephalitis as rare toxicity of immunotherapy treatment

After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center investigated why the complication occurred, performing a molecular analysis of the disease's pathology and mining data to determine the incidence of similar occurrences.

Скрыть анонс
19.07.2019
15:36 FierceBiotech.comHow a faulty gene that drives muscular dystrophy also shields cancer cells from immunotherapy

A team at the Fred Hutchinson Cancer Research Center has discovered that the mechanisms that activate the normally silenced gene DUX4 in a type of muscular dystrophy also help some cancer cells evade immune checkpoint inhibitors.

Скрыть анонс
07:58 News-Medical.NetStudy uncovers gene that hides tumor cells from immunotherapy

A team at Fred Hutchinson Cancer Research Center has identified a gene that could make immunotherapy treatments, specifically checkpoint inhibitors, work for a wider variety of cancer patients.

Скрыть анонс
01:09 ScienceDaily.comNew research identifies gene that hides cancer cells from immunotherapy

A team has identified a gene that could make immunotherapy treatments, specifically checkpoint inhibitors, work for a wider variety of cancer patients. The study found that when the DUX4 gene is expressed in cancer cells, it can prevent the cancer from being recognized and destroyed by the immune system.

Скрыть анонс
16.07.2019
12:09 News-Medical.NetUMass Amherst scientist receives $792,000 grant to advance cancer immunotherapy research

Biomedical engineer Ashish Kulkarni, assistant professor of chemical engineering at the University of Massachusetts Amherst, has been awarded a four-year, $792,000 grant from the American Cancer Society to advance his interdisciplinary lab's promising cancer immunotherapy research.

Скрыть анонс
12.07.2019
18:08 CancerNetwork.comCan SBRT Improve Immunotherapy Outcomes in Metastatic NSCLC?

A new study examined whether stereotactic body radiotherapy prior to pembrolizumab improved response rate in lung cancer patients.

Скрыть анонс
11:50 GizmagMIT supercharges cancer immunotherapy with a booster vaccine


Our bodies have powerful built-in defenses in the form of the immune system, but sometimes it needs an extra push. Chimeric Antigen Receptor (CAR) T cell therapy involves reprogramming T-cells to hunt down cancer, which has been effective against blood cancers but not so much against solid tumors. Now, scientists at MIT have found a way to supercharge the technique with a vaccine booster.
.. Continue Reading MIT supercharges cancer immunotherapy with a booster vaccine Category: Medical Tags: Breast cancer Cancer Cells Immunotherapy Leukemia Melanoma MIT The Immune System Vaccines

Скрыть анонс
08:00 News-Medical.NetAdding immunotherapy after initial treatment improves survival in metastatic NSCLC patients

Treating metastatic non-small cell lung cancer patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy – meaning all known sites of their cancer were either treated with surgery, radiation, or other definitive treatments – almost tripled the median progression-free survival compared to the historical average.

Скрыть анонс
10.07.2019
13:08 News-Medical.NetAMSBIO offers new, best-in-class CAR-T cell range for research and immunotherapy

AMSBIO announces new, best-in-class CAR-T cells, engineered CAR-T target cells, PBMC, cell media and activation beads in response to the rapid growth in research on the therapeutic uses of CAR-T cells.

Скрыть анонс
09.07.2019
19:54 ScienceDaily.comImmunotherapy could work against bowel cancers resistant to important targeted treatment

Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals. Scientists found that bowel tumours which had initially responded to cetuximab before developing resistance became more visible to the immune system -- potentially leaving them vulnerable to immunotherapies. A phase II clinical trial has already begun to test the possible benefit of immunotherapy in patients who have stopped responding to cetuximab.

Скрыть анонс
18:02 Drugs.comShould You Try Allergen Immunotherapy?

TUESDAY, July 9, 2019 -- If you're constantly sneezing and sniffling even though you take allergy medication to relieve symptoms, you may want to consider immunotherapy. This treatment is aimed at desensitizing you to your allergy triggers,...

Скрыть анонс
08.07.2019
18:35 NewScientist.ComImmunotherapy may help treat some resistant bowel cancers

A small study of drug-resistant bowel cancers suggests that it might be possible to treat these tumours using immunotherapy drugs

Скрыть анонс
18:05 FierceBiotech.comEngineered bacteria ‘prime’ solid tumors for immunotherapy

Arming the immune system so it can recognize and attack solid tumors has proven to be an illusive goal. Scientists at Columbia University hope to change that with an engineered form of the bacterium E. coli that's designed to colonize solid tumors. In mouse models, the treatment cleared primary tumors and reduced metastasis.

Скрыть анонс
11:36 Technology.orgImmune-boosting compound makes immunotherapy effective against pancreatic cancer

Pancreatic cancer is especially challenging to treat – only eight percent of patients are still alive five years

Скрыть анонс
04.07.2019
07:32 GizmagCompound puts pancreatic cancer in immunotherapy s sights


Immunotherapy is a form of cancer treatment that seeks to supercharge the body's natural immune defenses, and it's become a viable therapy for certain types of the disease. Pancreatic cancer is one that has so far been able to evade its advances, but scientists are now reporting a discovery that might help the immune system regain the upper hand.
.. Continue Reading Compound puts pancreatic cancer in immunotherapy's sights Category: Medical Tags: Cancer Immunotherapy Pancreatic cancer Washington University in St. Louis

Скрыть анонс
07:18 News-Medical.NetImmune-boosting compound could make pancreatic cancers susceptible to immunotherapy

Pancreatic cancer is especially challenging to treat – only eight percent of patients are still alive five years after diagnosis.

Скрыть анонс
03.07.2019
20:09 ScienceDaily.comBacteria engineered as Trojan horse for cancer immunotherapy

Researchers have engineered a strain of non-pathogenic bacteria that can colonize solid tumors in mice and safely deliver potent immunotherapies, acting as a Trojan Horse that treats tumors from within. The therapy led not only to complete tumor regression in a mouse model of lymphoma, but also significant control of distant, uninjected tumor lesions.

Скрыть анонс
14:28 TheDailyNewsEgypt.comEngineering new bacteria for cancer immunotherapy

Скрыть анонс
26.06.2019
13:21 News-Medical.NetNew findings could expand use of immunotherapy to fight cancers

More types of cancer could potentially be destroyed by patients’ own immune cells, thanks to new research by Cardiff University.

Скрыть анонс
25.06.2019
17:05 CancerNetwork.comCan a PARP Inhibitor Plus Immunotherapy Improve Recurrent Ovarian Cancer Outcomes?

A phase I/II trial tested the combination of niraparib and pembrolizumab in patients with recurrent ovarian carcinoma.

Скрыть анонс
19.06.2019
17:16 CancerNetwork.comDr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma Patients

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.

Скрыть анонс
16:39 CancerNetwork.comCombination Immunotherapy Efficacy in Lung Cancer May Differ by Patient Sex

A study in the Journal of the National Cancer Institute evaluated responses in men vs women to combination chemotherapy and a PD-1 or PD-L1 inhibitor.

Скрыть анонс
14.06.2019
10:45 News-Medical.NetDeveloping new immunotherapeutic treatments for emerging viral diseases

Emerging viral diseases is a term used to refer to diseases caused by pathogens such as the Ebola virus. Whilst vaccines can protect people against these diseases, there is an urgent need for treatment options after infection.

Скрыть анонс
13.06.2019
22:57 CancerNetwork.comDr. Janice M. Mehnert on Immunotherapy vs BRAF/MEK Inhibitors in the Adjuvant Setting for Melanoma

Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.

Скрыть анонс
22:22 CancerNetwork.comDr. Thomas Gajewski on Analyzing the Tumor Microenvironment to Guide Immunotherapy in Melanoma

Cancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.

Скрыть анонс
11:21 Technology.orgImmunotherapy Drug Shows Potential to Cure Advanced Lung Cancer

In a new study including Yale Cancer Center and Smilow Cancer Hospital researchers, the cancer immunotherapy drug pembrolizumab

Скрыть анонс
12.06.2019
21:48 CancerNetwork.comDr. Ryan J. Sullivan on Frontline Immunotherapy Sequencing in Melanoma

Cancer Network spoke with Ryan J. Sullivan, MD, of Massachusetts General Hospital, about the debate between immunotherapy sequencing vs targeted therapy for melanoma.

Скрыть анонс
11.06.2019
16:43 CancerNetwork.comDo Brain Metastases Rule Out Immunotherapy in RCC?

An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases.

Скрыть анонс
10.06.2019
22:41 CancerNetwork.comEffect of Anti-Angiogenesis/Immunotherapy Combo in Poor-Risk RCC

Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology.

Скрыть анонс
12:24 Technology.orgImmunotherapy Delays Type 1 Diabetes Onset in People at High Risk

A two-week course of an experimental immunotherapy called teplizumab dramatically reduced type 1 diabetes (T1D) diagnosis rates in

Скрыть анонс
07.06.2019
11:30 ClinicalOncology.comAntibiotics May Blunt Cancer Immunotherapy Response

San Francisco—Cancer patients who received antibiotics within 60 days of starting immunotherapy were significantly less likely to respond to cancer treatment than those not receiving antibiotics, researchers reported at the 2019 Gastrointestinal Cancers Symposium.

Скрыть анонс
05.06.2019
00:11 CancerNetwork.comAnti-BCMA BiTE Immunotherapy: An Option for R/R Multiple Myeloma?

Data from the first-in-human study of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, were presented at ASCO 2019.

Скрыть анонс
04.06.2019
18:09 CancerNetwork.comILLUMINATE 301 Will Study Experimental Immunotherapy for Patients With Advanced Melanoma

Investigators are now enrolling for a phase III trial testing the experimental immunotherapy tilsotolimod plus ipilimumab in patients with advanced melanoma who have progressed on anti–PD-1 therapy.

Скрыть анонс
17:45 CancerNetwork.comPatient-Reported Quality of Life Maintained With Immunotherapy for Advanced Melanoma

The phase III CheckMate 067 study looked at patient-reported quality-of-life outcomes in patients with advanced melanoma undergoing immunotherapy treatment.

Скрыть анонс
09:08 News-Medical.NetResearchers develop novel imaging test to predict immunotherapy response in kidney cancer

A novel imaging test shows promise for identifying kidney cancer patients most likely to benefit from immunotherapy.

Скрыть анонс
03.06.2019
23:55 ScienceDaily.comImmunotherapy drug found safe in treating cancer patients with HIV, study suggests

The results of a new study suggest that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA.

Скрыть анонс
15:27 News-Medical.NetCombination immunotherapy shows promise in pre-surgical setting for early-stage lung cancers

Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery.

Скрыть анонс
12:26 Technology.orgAfter 2 Years, Immunotherapy Shows Doubled Median Survival Time for Advanced Lung Cancer Patients

A large, randomized immunotherapy clinical trial continues to show improved overall survival and progression-free survival in advanced lung

Скрыть анонс
09:59 News-Medical.NetImmunotherapy increases five-year survival rate of patients with advanced non-small cell lung cancer

In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years - and 25% of patients whose tumor cells had a specific protein lived at least that long.

Скрыть анонс
31.05.2019
10:03 News-Medical.NetIU researchers, collaborators receive grant to develop immunotherapy treatments for cancer

A team of researchers from Indiana University and Memorial Sloan Kettering Cancer Center have been awarded a $4.1 million National Cancer Institute "Cancer Moonshot" grant to develop immunotherapy treatments for cancer in children and adolescents, especially those with leukemia.

Скрыть анонс
21.05.2019
16:21 News-Medical.NetImmunotherapy is the most prominent topic in skin cancer research, report reveals

A new report published today highlights the different research areas in the field of skin cancer, showing that immunotherapy is the most prominent topic and reveals the countries that are driving this research.

Скрыть анонс
00:54 CancerNetwork.comAutoimmune Skin Toxicities Linked With Response to Immunotherapy in Lung Cancer

A new study identified several T-cell antigens that are shared between tumor tissue and skin in a cohort of patients with non–small-cell lung cancer who were treated with anti–PD-1 therapy.

Скрыть анонс
15.05.2019
19:47 Medscape.ComFDA Okays Another Immunotherapy Plus TKI for Advanced RCC

The FDA has approved avelumab in combination with the tyrosine kinase inhibitor (TKI) axitinib for the first-line treatment of advanced renal cell carcinoma (RCC).

Скрыть анонс
13.05.2019
18:55 CancerNetwork.comNatural Killer Cell Levels Could Influence Immunotherapy Outcomes for Lymphoma

Patients with follicular lymphoma or diffuse large B-cell lymphoma with a low peripheral blood natural killer cell count at baseline had shorter time to progression.

Скрыть анонс
10.05.2019
11:18 ClinicalOncology.comAntibiotics May Blunt Cancer Immunotherapy Response

San Francisco—Cancer patients who received antibiotics within 60 days of starting immunotherapy were significantly less likely to respond to cancer treatment than those not receiving antibiotics, researchers reported at the 2019 Gastrointestinal Cancers Symposium.

Скрыть анонс
07.05.2019
22:49 ScienceDaily.comTumor mutations may predict response to immunotherapy

Researchers say they have found a potential explanation for the failures.

Скрыть анонс
06.05.2019
22:38 Nanowerk.comNanovaccine design can dramatically improve cancer immunotherapies

Effectiveness depends on molecular architecture and 3D presentation of components.

Скрыть анонс
22:01 Phys.orgVaccine design can dramatically improve cancer immunotherapies

When it comes to the effectiveness of nanotherapeutic vaccines, shape matters.

Скрыть анонс
03.05.2019
15:31 CancerNetwork.comReview Touts Benefits of Immunotherapy for Non-Melanoma Skin Cancers

The authors discuss the potential use and limitations of immunotherapy among patients with squamous cell cancer, basal cell carcinoma, and other skin cancers.

Скрыть анонс
10:08 Technology.orgResearchers Find New Target to Improve Response to Cancer Immunotherapy

New findings suggest an unexpected path to killing cancer cells could make the hottest cancer treatment — immunotherapy

Скрыть анонс
02.05.2019
17:38 ScienceDaily.comPretreatment with TNF inhibitors may improve outcomes of combination cancer immunotherapy

This study proposes a new therapeutic approach against cancer that dissociates efficacy and toxicity in the use of combined immunotherapy in animal models. This clinical strategy consists of blocking TNF protein while applying combination immunotherapy treatment (inhibition therapy of PD-1 and CTLA-4, other proteins that 'slow down' the immune response).

Скрыть анонс
10:22 Reuters.com HealthAstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

Скрыть анонс
01.05.2019
22:54 ScienceDaily.comNew target to improve response to cancer immunotherapy

Researchers have looked at a little-understood type of cell death called ferroptosis. They found ferroptosis occurs in tumor cells and plays a role in cancer immunity, suggesting the potential of targeting this pathway to improve immunotherapy treatments.

Скрыть анонс
20:17 Nature.ComProphylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Скрыть анонс
20:17 Nature.ComCD8

Скрыть анонс
30.04.2019
22:43 Medscape.ComPeanut Oral Immunotherapy May Increase Risk for Anaphylaxis

A new review finds that oral immunotherapy for peanut allergy may result in desensitization but is associated with more anaphylaxis events.

Скрыть анонс
18:05 CancerNetwork.comCombo Immunotherapy Failed to Improve Outcomes in MSS Colorectal Cancer

A phase III trial examined immunotherapy in patients with microsatellite-stable metastatic colorectal cancer.

Скрыть анонс
11:08 News-Medical.NetAngiotensin receptor blockers could improve response to cancer immunotherapy

A research team led by investigators at Massachusetts General Hospital and the Massachusetts Institute of Technology has found that combining a specialized version of an antihypertension drug with immune checkpoint blockers could increase the effectiveness of cancer immunotherapies.

Скрыть анонс
29.04.2019
07:14 GizmagMeta-study suggests peanut immunotherapy may actually increase allergic reactions


A systematic meta-analysis of a dozen trials into the efficacy of an oral immunotherapy treatment designed to reduce allergic reactions to peanuts has concluded the treatment may work in clinical environments however it paradoxically results in patients suffering from more real-world adverse allergic events than people who simply avoided peanuts altogether.
.. Continue Reading Meta-study suggests peanut immunotherapy may actually increase allergic reactions Category: Health & Wellbeing Tags: Allergies Immunotherapy Peanut

Скрыть анонс
04:58 CancerNetwork.comRecent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma

Dr. Balar highlights promising evidence on the potential benefits of the use of immunotherapy in the advanced bladder cancer setting.

Скрыть анонс
04:58 CancerNetwork.comCombining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer

Dr. McArthur discusses the latest results of immunotherapy trials in the treatment of triple-negative breast cancer.

Скрыть анонс
26.04.2019
19:23 Google news HealthOral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety - The Lancet

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety  The LancetPeanut Allergy Immunotherapy Increases Anaphylaxis Risk: Study  The ScientistPeanut exposure may not work for peanut allergy  NewsyA Promising Peanut Allergy Treatment May Not Work So Well After All, Research Review Says  TIMEExperimental treatment for peanut allergy increases anaphylaxis risk, study finds  CNNView full coverage on Google News

Скрыть анонс
19:23 Google news Sci/TechOral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety - The Lancet

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety  The LancetPeanut Allergy Immunotherapy Increases Anaphylaxis Risk: Study  The ScientistPeanut exposure may not work for peanut allergy  NewsyA Promising Peanut Allergy Treatment May Not Work So Well After All, Research Review Says  TIMEExperimental treatment for peanut allergy increases anaphylaxis risk, study finds  CNNView full coverage on Google News

Скрыть анонс
13:01 Technology.orgStudy pinpoints what causes relapse after cancer immunotherapy

Harnessing the body’s immune system to fight off cancer, a tactic known as immunotherapy, has tremendously improved outcomes

Скрыть анонс
03:36 Drugs.comIs Peanut Allergy 'Immunotherapy' Causing More Harm Than Good?

THURSDAY, April 25, 2019 -- The idea behind immunotherapy for peanut allergy is appealing in its simplicity: Ask a patient to eat tiny amounts of peanut every day, and over time their immune system will become desensitized to it. Unfortunately, this...

Скрыть анонс
01:54 NewScientist.ComPeanut allergy immunotherapy may actually do more harm than good

Treatments intended to desensitise people to peanuts had shown promise in tests, but an analysis suggests they may make dangerous allergic reactions more likely

Скрыть анонс
17.04.2019
19:01 ScienceDaily.comOral immunotherapy safe for preschool-aged children with peanut allergies, study suggests

New data suggests that oral immunotherapy offered as routine treatment in a hospital or clinic is safe for preschool-aged children with peanut allergies.

Скрыть анонс
16:44 StemCellsPortal.comlCancers 'change spots' to avoid immunotherapy

LONDON (UK), April 2019 — Cancers can make themselves harder for new immunotherapies to see by “changing their spots” — and switching off a key molecule on the surface of cells that is otherwise recognized by treatment.
Researchers found that they could test samples from patients with bowel cancer to identify which were most likely to respond to immunotherapy by assessing molecular changes within miniature tumors grown in the laboratory.
Using the mini tumors, the researchers identified existing drugs that could potentially be used in combination with immunotherapy to make it work for many more patients.
The team at the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Foundation Trust believe their findings could help increase the effectiveness of the antibody-based drug cibisatamab and open up ways of assessing whether patients will respond to immunotherapy

Скрыть анонс
15.04.2019
17:40 ScienceDaily.comCancers 'change spots' to avoid immunotherapy

Cancers can make themselves harder for new immunotherapies to see by 'changing their spots' -- and switching off a key molecule on the surface of cells that is otherwise recognised by treatment.

Скрыть анонс
09:54 News-Medical.NetCancer cells use tactics to avoid being recognised by immunotherapy agents

Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy agents.

Скрыть анонс
07:39 News-Medical.NetCancers avoid immunotherapies by 'changing their spots'

Cancers can make themselves harder for new immunotherapies to see by 'changing their spots' - and switching off a key molecule on the surface of cells that is otherwise recognized by treatment.

Скрыть анонс
12.04.2019
16:46 StemCellsPortal.comlImmunotherapy kicks, kills HIV by exploiting common virus

PITTSBURGH, , A (US), April 2019 — In a first on the quest to cure HIV, University of Pittsburgh Graduate School of Public Health scientists report in EBioMedicine that they’ve developed an all-in-one immunotherapy approach that not only kicks HIV out of hiding in the immune system, but also kills it.
The key lies in immune cells designed to recognize an entirely different virus. 
The discovery, made in the laboratory using cells from people with HIV, is yet to be tested in clinical trials, but could lead to the development of a vaccine that would allow people positive for HIV to stop taking daily medications to keep the virus in check.  
“A lot of scientists are trying to develop a cure for HIV, and it’s usually built around the ‘kick and kill’ concept – kick the virus out of hiding and

Скрыть анонс
08.04.2019
17:46 News-Medical.NetNew clinical trials to investigate combination immunotherapy for treating advanced cancers

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission.

Скрыть анонс
11:54 Technology.orgImmunotherapy Kicks, Kills HIV by Exploiting a Common Virus

In a first on the quest to cure HIV, University of Pittsburgh Graduate School of Public Health scientists report in EBioMedicine that

Скрыть анонс
05:31 News-Medical.NetNew HIV drug that is like a "Swiss Army knife of immunotherapies"

HIV is a tricky virus that causes a unique phenomenon where the virus hides within the immune cells of patients when they are on treatment with the antiretroviral therapy (ART) drugs. When they are off the drugs, the virus comes back.

Скрыть анонс
05.04.2019
22:07 ScienceMag.orgFecal transplants could help patients on cancer immunotherapy drugs

Early results hint that benefits seen in mice could extend to people

Скрыть анонс
17:08 News-Medical.NetPatients on immunotherapies should consume more fiber, fewer probiotics

A new study has found that taking probiotics could drastically reduce the response of cancer patients to immunotherapy. Patients on a fiber-rich diet showed a five-fold increase in response.

Скрыть анонс
13:04 CancerNetwork.comPrecursor Immunotherapy to Prevent Squamous Cell Carcinoma

Researchers evaluated whether treatment with calcipotriol plus 5-fluorouracil aided in reducing the risk of squamous cell carcinoma.

Скрыть анонс
11:49 Technology.orgUrine Test to Evaluate Immunotherapy Success Gets $1.8 Million NIH Research Grant

New immunotherapies can dramatically defeat cancer. But more often, cancer evades them, and doctors need to know quickly

Скрыть анонс
First← Previous12345678910Previous →Last